Decreased Levels of Serum IGF-1 and Vitamin D Are Associated With Cognitive Impairment in Patients With Type 2 Diabetes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Sage Publications Country of Publication: United States NLM ID: 101082834 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-2731 (Electronic) Linking ISSN: 15333175 NLM ISO Abbreviation: Am J Alzheimers Dis Other Demen Subsets: MEDLINE
    • Publication Information:
      Publication: Thousand Oaks, Calif. : Sage Publications
      Original Publication: Weston, MA : Prime National Pub. Corp., c2000-
    • Subject Terms:
      Calcifediol/*blood ; Cognitive Dysfunction/*blood ; Diabetes Complications/*blood ; Diabetes Mellitus, Type 2/*blood ; Insulin-Like Growth Factor I/*metabolism; Aged ; Cognitive Dysfunction/etiology ; Diabetes Mellitus, Type 2/complications ; Female ; Humans ; Male ; Middle Aged
    • Abstract:
      Purpose: To determine the association of serum insulin-like growth factor 1 (IGF-1) and vitamin D levels with cognition status in patients with type 2 diabetes mellitus (T2DM).
      Methods: A total of 173 patients with T2DM were recruited and divided into mild cognitive impairment (MCI) group (n = 94) and normal cognition (NC) group (n = 79). Levels of IGF-1 and 25(OH)D were measured and compared, and the correlations among IGF-1, 25(OH)D, and cognitive function were analyzed.
      Results: Insulin-like growth factor 1 and 25(OH)D levels significantly decreased in MCI group than those in the NC group (both P < .001). Multiple stepwise regression analysis revealed that IGF-1 (β = .146, P < .001) and 25(OH)D (β = .199, P < .001) independently predicted Montreal Cognitive Assessment (MoCA) scores. Partial least square regression showed that contributions of both 25(OH)D ( P < .001) and IGF-1 ( P < .001) to MoCA scores were significant, while no cross-effect was observed between them ( P = .714).
      Conclusions: Low serum IGF-1 and 25(OH)D levels may separately predict poor cognitive performance in patients with diabetes.
    • References:
      Intern Med J. 2012 May;42(5):484-91. (PMID: 22372522)
      J Neurosci Res. 2006 May 15;83(7):1179-89. (PMID: 16521124)
      Growth Horm IGF Res. 2016 Oct - Dec;30-31:45-51. (PMID: 27863277)
      J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):714-8. (PMID: 16549412)
      J Alzheimers Dis. 2016 Mar 29;52(2):641-9. (PMID: 27031487)
      J Am Geriatr Soc. 2005 Oct;53(10):1748-53. (PMID: 16181175)
      BMJ. 2010 Aug 05;341:c3885. (PMID: 20688841)
      Appl Neuropsychol Adult. 2018 Nov-Dec;25(6):562-571. (PMID: 28880690)
      Growth Horm IGF Res. 2017 Apr;33:35-42. (PMID: 28372721)
      Neurology. 2017 Aug 29;89(9):918-926. (PMID: 28768841)
      Neurochem Res. 2006 Apr;31(4):533-9. (PMID: 16758362)
      Neurodegener Dis. 2014;13(2-3):75-81. (PMID: 24192346)
      Neurol Sci. 2016 Oct;37(10):1671-7. (PMID: 27379655)
      Eur J Endocrinol. 2013 Oct 21;169(6):767-72. (PMID: 24005315)
      Arch Neurol. 1999 Mar;56(3):303-8. (PMID: 10190820)
      Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7537-42. (PMID: 9207127)
      Clin Endocrinol (Oxf). 2015 Jul;83(1):36-42. (PMID: 25641087)
      Am J Alzheimers Dis Other Demen. 2016 Nov;31(7):564-569. (PMID: 27303061)
      J Nutr. 2000 May;130(5):1147-52. (PMID: 10801911)
      Gen Comp Endocrinol. 2014 Sep 1;205:296-304. (PMID: 24882593)
      J Am Geriatr Soc. 2017 Oct;65(10):2161-2168. (PMID: 28758188)
      Int Urol Nephrol. 2013 Dec;45(6):1637-46. (PMID: 23636430)
      Diabetes Res Clin Pract. 2008 Dec;82(3):305-9. (PMID: 18848366)
      J Ment Health. 2016;25(2):131-6. (PMID: 26758526)
      J Neurosci Res. 2008 May 1;86(6):1397-408. (PMID: 18183618)
      Int J Mol Sci. 2017 Nov 17;18(11):. (PMID: 29149058)
      Dement Geriatr Cogn Disord. 2012;33(5):297-305. (PMID: 22759681)
      J Neurol Sci. 2012 Nov 15;322(1-2):152-6. (PMID: 22871541)
      Br J Clin Pharmacol. 2011 Mar;71(3):365-76. (PMID: 21284695)
      PLoS One. 2016 Apr 26;11(4):e0154450. (PMID: 27115487)
      Dement Geriatr Cogn Disord. 2015;39(5-6):251-6. (PMID: 25661865)
      Clin Endocrinol (Oxf). 2013 Oct;79(4):457-63. (PMID: 23789983)
      Int J Clin Pract. 2010 Feb;64(3):351-5. (PMID: 19863680)
      Neurobiol Aging. 2015 Feb;36(2):942-7. (PMID: 25467636)
      Ageing Res Rev. 2018 Mar;42:14-27. (PMID: 29233786)
      PLoS One. 2015 May 26;10(5):e0127574. (PMID: 26010883)
      Biomed Res Int. 2013;2013:186106. (PMID: 23936778)
    • Contributed Indexing:
      Keywords: IGF-1; Montreal Cognitive Assessment; diabetes mellitus; mental status and dementia tests; mild cognitive impairment; type 2; vitamin D
    • Accession Number:
      0 (IGF1 protein, human)
      67763-96-6 (Insulin-Like Growth Factor I)
      P6YZ13C99Q (Calcifediol)
    • Publication Date:
      Date Created: 20190720 Date Completed: 20200710 Latest Revision: 20240402
    • Publication Date:
      20240402
    • Accession Number:
      PMC10653368
    • Accession Number:
      10.1177/1533317519860334
    • Accession Number:
      31319676